Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Malignant Solid TumourBiliary CancerPancreatic Cancer
Interventions
DRUG

Gemcitabine

Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.

DRUG

Capecitabine

Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.

DRUG

ZD6474

Administered orally at 300 mg/day once daily. One cycle will consist of 28 days

Trial Locations (1)

80045

University of Colorado Denver, Aurora

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Colorado, Denver

OTHER